Using past pregnancy records from women with sickle cell
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This study looks back at past pregnancy and breastfeeding experiences in women with sickle cell disease who took hydroxyurea. It aims to better understand how hydroxyurea exposure may affect pregnancy and baby outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are pregnant or have been pregnant and have a diagnosis of sickle cell disease
- You had any hydroxyurea exposure during pregnancy and/or while breastfeeding
- You have past medical records for pregnancy and baby outcomes available before June 20, 2019
- These records should include details about the pregnancy and/or breastfeeding outcomes
- You also need information that confirms you took hydroxyurea during that time
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial program studies sickle cell disease and how treatment works, especially for people who are already taking hydroxyurea at a stable, maximum tolerated dose. It may help researchers better understand treatment effects and side effects in real patients.
This trial tests a way to use hydroxyurea more safely and effectively in children with sickle cell anemia. It may help doctors fine-tune dosing to reduce complications and side effects.
This trial checks whether monitoring hydroxyurea drug levels in the blood can help doctors find the best dose for sickle cell patients. It focuses on people with HbSS who have recently had a pain crisis or whose current dose isn't working.
This study asks mothers of babies with sickle cell disease about early-life exposures and related factors. It may help researchers understand what might affect health in the first months of life.
This trial tests a new twice-daily liquid form of hydroxyurea (a common SCD medicine) in children ages 9 months to 11 years with sickle cell disease. It will check how the medicine works in the body, if it is safe, and if it helps reduce pain crises and other complications.
This study is developing a risk assessment tool to help predict complications in pregnant women with sickle cell disease. It reviews medical records from women who have received prenatal care and given birth at participating hospitals.
Hear when a new Sickle Cell Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.